888-969-2592
Kalkine 0
countryflagCA

Gilead Sciences Inc

Healthcare US GILD

108.51USD
-0.29(0.27%)

Last update at 2025-07-18T16:59:00Z

Day Range

108.53110.90
LowHigh

52 Week Range

63.7486.98
LowHigh

Fundamentals

  • Previous Close 108.80
  • Market Cap79659.65M
  • Volume1960582
  • P/E Ratio182.69
  • Dividend Yield4.69%
  • EBITDA12665.00M
  • Revenue TTM27450.00M
  • Revenue Per Share TTM22.00
  • Gross Profit TTM 21624.00M
  • Diluted EPS TTM0.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 5814.00M 8278.00M 1669.00M 5160.00M 7799.00M
Minority interest 26.00M 24.00M -34.00000M -22.00000M 5.00M
Net income 4592.00M 6225.00M 89.00M 5386.00M 5455.00M
Selling general administrative 5673.00M 5246.00M 5151.00M 4381.00M 4056.00M
Selling and marketing expenses - - - - -
Gross profit 21624.00M 20704.00M 20117.00M 17774.00M 17274.00M
Reconciled depreciation 2103.00M 2050.00M 1480.00M 1404.00M 1429.00M
Ebit 7330.00M 7406.00M 7029.00M 4287.00M 7447.00M
Ebitda 10393.00M 9456.00M 8509.00M 6155.00M 8876.00M
Depreciation and amortization 3063.00M 2050.00M 1480.00M 1868.00M 1429.00M
Non operating income net other -581.00000M -639.00000M -1418.00000M 1868.00M 676.00M
Operating income 7330.00M 7406.00M 7029.00M 4287.00M 8200.00M
Other operating expenses 16307.00M 17210.00M 14762.00M 18162.00M 13927.00M
Interest expense 935.00M 1001.00M 984.00M 995.00M 1077.00M
Tax provision 1248.00M 2077.00M 1580.00M -204.00000M 2339.00M
Interest income - - - 227.00M 964.00M
Net interest income -935.00000M -1001.00000M -984.00000M -995.00000M -1077.00000M
Extraordinary items - - - - -4.00000M
Non recurring 3644.00M - - - -
Other items - - - - -
Income tax expense 1248.00M 2077.00M 1580.00M -204.00000M 2339.00M
Total revenue 27281.00M 27305.00M 24689.00M 22449.00M 22127.00M
Total operating expenses 10650.00M 10609.00M 10190.00M 13487.00M 9074.00M
Cost of revenue 5657.00M 6601.00M 4572.00M 4675.00M 4853.00M
Total other income expense net -1516.00000M 872.00M -5360.00000M 873.00M 676.00M
Discontinued operations - - - - -
Net income from continuing ops 4566.00M 6201.00M 89.00M 5364.00M 5460.00M
Net income applicable to common shares 4592.00M 6225.00M 123.00M 5386.00M 5455.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 62125.00M 63171.00M 67952.00M 68407.00M 61627.00M
Intangible assets 26454.00M 28894.00M 33455.00M 33126.00M 13786.00M
Earning assets - - - - -
Other current assets 2374.00M 1774.00M 2141.00M 2013.00M 1440.00M
Total liab 39376.00M 41962.00M 46888.00M 50186.00M 38977.00M
Total stockholder equity 22749.00M 21209.00M 21064.00M 18221.00M 22650.00M
Deferred long term liab - 2673.00M 4356.00M - -
Other current liab 11280.00M 8059.00M 9389.00M 7796.00M 6547.00M
Common stock 1.00M 1.00M 1.00M 1.00M 1.00M
Capital stock 1.00M 1.00M 1.00M 1.00M 1.00M
Retained earnings 16304.00M 15687.00M 16324.00M 14381.00M 19388.00M
Other liab - 7301.00M 35278.00M 9536.00M 6498.00M
Good will 8314.00M 8314.00M 8332.00M 8108.00M 4117.00M
Other assets - 1.00M 5988.00M 4799.00M 3119.00M
Cash 6085.00M 5412.00M 5338.00M 5997.00M 11631.00M
Cash and equivalents - - - - -
Total current liabilities 11280.00M 11237.00M 11610.00M 11397.00M 9759.00M
Current deferred revenue -2348.00000M - - - -
Net debt 18902.00M 19818.00M 21357.00M 25405.00M 12962.00M
Short term debt 1798.00M 2273.00M 1516.00M 2757.00M 2499.00M
Short long term debt 1798.00M 2273.00M 1516.00M 2757.00M 2499.00M
Short long term debt total 24987.00M 25230.00M 26695.00M 31402.00M 24593.00M
Other stockholder equity -16332.00000M 5519.00M 4656.00M 3899.00M 3176.00M
Property plant equipment - 5475.00M 5121.00M 4967.00M 4502.00M
Total current assets 16454.00M 15227.00M 15056.00M 15816.00M 31489.00M
Long term investments 1163.00M 1245.00M 1309.00M 502.00M 1488.00M
Net tangible assets - -15968.00000M -20723.00000M -23032.00000M 4622.00M
Short term investments 1179.00M 973.00M 1182.00M 1411.00M 12721.00M
Net receivables 4660.00M 4777.00M 4493.00M 4892.00M 3582.00M
Long term debt 23189.00M 22957.00M 25179.00M 28645.00M 22094.00M
Inventory 3366.00M 2820.00M 2734.00M 3014.00M 2067.00M
Accounts payable 550.00M 905.00M 705.00M 844.00M 713.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity -84.00000M -31.00000M -5.00000M 19.00M 125.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 28.00M 2.00M 83.00M -60.00000M 85.00M
Additional paid in capital 6500.00M - - - -
Common stock total equity - 1.00M 1.00M 1.00M 1.00M
Preferred stock total equity - - - - -
Retained earnings total equity - 15687.00M 16324.00M 14381.00M 19388.00M
Treasury stock 0.00000M - - - -
Accumulated amortization - - - - -
Non currrent assets other 5586.00M 4016.00M 5988.00M 6390.00M 7733.00M
Deferred long term asset charges - - - - -
Non current assets total 45671.00M 47944.00M 52896.00M 52591.00M 30138.00M
Capital lease obligations - - - - -
Long term debt total - 22957.00M 25179.00M 28645.00M 22094.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2466.00000M -3131.00000M 11948.00M -2307.00000M 15279.00M
Change to liabilities -1117.00000M 207.00M -58.00000M -178.00000M -2012.00000M
Total cashflows from investing activities -2466.00000M -3131.00000M -14615.00000M -7817.00000M 14355.00M
Net borrowings -1500.00000M -4750.00000M 5684.00M -2750.00000M -6250.00000M
Total cash from financing activities -6469.00000M -8877.00000M 770.00M -7634.00000M -12318.00000M
Change to operating activities -705.00000M 647.00M 426.00M -696.00000M 389.00M
Net income 4566.00M 6201.00M 89.00M 5364.00M 5460.00M
Change in cash 74.00M -659.00000M -5634.00000M -6309.00000M 10352.00M
Begin period cash flow 5338.00M 5997.00M 11631.00M 17940.00M 7588.00M
End period cash flow 5412.00M 5338.00M 5997.00M 11631.00M 17940.00M
Total cash from operating activities 9072.00M 11384.00M 8168.00M 9144.00M 8400.00M
Issuance of capital stock 309.00M 169.00M 256.00M 209.00M 289.00M
Depreciation 2103.00M 2050.00M 1480.00M 1404.00M 1429.00M
Other cashflows from investing activities -1798.00000M -3131.00000M -25913.00000M -4685.00000M -190.00000M
Dividends paid -3709.00000M -3605.00000M -3449.00000M -3222.00000M 2971.00M
Change to inventory -310.00000M 11.00M -195.00000M -95.00000M -310.00000M
Change to account receivables -406.00000M 313.00M -1171.00000M -218.00000M 480.00M
Sale purchase of stock -1396.00000M -546.00000M -1583.00000M -1749.00000M -2900.00000M
Other cashflows from financing activities -173.00000M -145.00000M 8046.00M -122.00000M -486.00000M
Change to netincome 3509.00M 11384.00M 6535.00M -478.00000M 2010.00M
Capital expenditures 728.00M 579.00M 650.00M 825.00M 924.00M
Change receivables -406.00000M 313.00M -1171.00000M -218.00000M 480.00M
Cash flows other operating 727.00M 689.00M 1488.00M 3345.00M 1343.00M
Exchange rate changes - - - - -85.00000M
Cash and cash equivalents changes 137.00M -624.00000M -5677.00000M -6307.00000M 10352.00M
Change in working capital -1763.00000M 489.00M -1638.00000M -798.00000M -939.00000M
Stock based compensation 637.00M 635.00M 643.00M 636.00M 845.00M
Other non cash items 5081.00M 2125.00M 7808.00M 4636.00M 1316.00M
Free cash flow 8344.00M 10805.00M 7518.00M 8319.00M 7476.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GILD
Gilead Sciences Inc		 -0.29 0.27% 108.51 182.69 9.64 3.13 3.72 3.78 9.78
LLY
Eli Lilly and Company		 9.37 1.23% 770.87 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 1.15 0.71% 164.13 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 -2.52 1.32% 188.88 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 -1.31 1.61% 80.21 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc

333 Lakeside Drive, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Mr. Daniel P. O'Day Chairman & CEO 1964
Mr. Andrew D. Dickinson Exec. VP & CFO 1970
Ms. Johanna Mercier Chief Commercial Officer 1970
Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer 1963
Ms. Diane E. Wilfong Sr. VP, Corp. Controller & Chief Accounting Officer 1962
Ms. Jacquie Ross C.F.A. VP of Investor Relations NA
Ms. Deborah H. Telman Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. 1965
Ms. Jyoti K. Mehra Exec. VP of HR 1976
Dr. Michael Quigley Ph.D. Sr. VP of Research Biology NA
Dr. Linda Slanec Higgins Ph.D. Sr. VP & Head of External Innovation 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.